|Mr. Stefan Weber||CEO & Exec. Director||459.83k||N/A||1965|
|Mr. Roberto Galli||VP of Fin.||N/A||N/A||N/A|
|Mr. Marco Caremi||Exec. VP of Bus. Devel.||N/A||N/A||1957|
|Dr. Ravi Anand||Chief Medical Officer||1.17M||N/A||1957|
Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development, manufacture, and distribution of therapies for the treatment of central and peripheral nervous system, and pain in Italy and the United States. The company offers Xadago (safinamide) for the treatment of Parkinson's disease. Its product pipeline comprises Evenamide, a first add-on therapy for the treatment of patients with positive symptoms of schizophrenia; and Ralfinamide for patients with specific rare pain indications. Newron Pharmaceuticals S.p.A. was founded in 1999 and is headquartered in Bresso, Italy.
Newron Pharmaceuticals S.p.A.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.